长春高新下属公司签署GenSci098注射液项目独家许可协议

Core Viewpoint - Changchun Gaoxin announced a licensing agreement with Yarrow Bioscience for the GenSci098 injection project, which is expected to generate significant financial benefits for the company [1] Financial Summary - The agreement includes an upfront payment of $120 million, consisting of a non-refundable and non-offsettable payment of $70 million and a subsequent milestone payment of $50 million [1] - Additionally, the company is eligible for up to $1.365 billion in milestone payments related to specific R&D, regulatory, and commercialization achievements [1] - After the product launch, the company will receive over 10% of net sales as a royalty [1]